Organogenesis Holdings, Inc. Class A ORGO 深 沪
已收盘 04-02 16:00:00 美东时间
2.24
-0.070
-3.03%
华盛通- 最 高2.29
- 今 开2.28
- 成交量 50.73万股
- 最 低 2.21
- 昨 收 2.31
- 总市值 2.88亿
- 52周最高 7.0771
- 市盈率 静 14.57
- 换手率 0.39%
- 52周最低 2.21
- 委 比 -60.74%
- 总股本 1.29亿
- 历史最高 310.90
- 量 比 0.89
- 振 幅 3.46%
- 历史最低 1.795
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
BTIG Reiterates Buy on Organogenesis Holdings, Maintains $8 Price Target
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Buy and maintains $8 price target.
03-26 17:43
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
BTIG Maintains Buy on Organogenesis Holdings, Lowers Price Target to $8
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and lowers the price target from $9 to $8.
02-27 18:35
Organogenesis Holdings Sees FY2026 Sales $350.000M-$420.000M vs $543.400M Est.
Organogenesis Holdings (NASDAQ:ORGO) sees FY2026 sales of $350.000 million-$420.000 million vs $543.400 million analyst estimate.
02-27 05:26
Organogenesis Holdings Q4 Earnings Report: What Investors Need to Know
Organogenesis Holdings (NASDAQ:ORGO) reported its Q4 earnings results on Thursd...
02-27 05:26
Organogenesis Hldgs Q4 Adj. EPS $0.40 Beats $0.21 Estimate, Sales $225.607M Beat $172.700M Estimate.
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.21 by 90.48 percent. This is a 471.43 percent increase over earnings of $0.07 per share
02-27 05:25
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
A Preview Of Organogenesis Hldgs's Earnings
Organogenesis Hldgs (NASDAQ:ORGO) will release its quarterly earnings report on...
02-26 03:01
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
